Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04169529 · ClinicalTrials.gov registry record
Reveal LINQ for Chronic Obstructive Pulmonary Disease (COPD)
A clinical trial, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Completed
- Registry status
- 42
- Enrollment target
NCT04169529 is a clinical trial that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 42 participants.
The verdict
NCT04169529 has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
The purpose of the LINQ™ for COPD study is to characterize Reveal LINQ™ derived data from patients with COPD by assessing the relationship between changes in LINQ™ derived data with COPD exacerbation events.
Interventions
- DEVICE Reveal LINQ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2020-08-25 |
| Est. Completion | 2023-06-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04169529
The ClinicalTrials.gov registry entry for NCT04169529 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Rhythm and Heart Failure, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Reveal LINQ is the first listed.
NCT04169529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04169529 about?
NCT04169529 is a clinical study titled "Reveal LINQ for Chronic Obstructive Pulmonary Disease (COPD)". The purpose of the LINQ™ for COPD study is to characterize Reveal LINQ™ derived data from patients with COPD by assessing the relationship between changes in LINQ™ derived data with COPD exacerbation events.
What is the current status of trial NCT04169529?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2020-08-25. Estimated completion is 2023-06-27.
What interventions are being tested in trial NCT04169529?
The interventions under investigation include: Reveal LINQ (DEVICE).
Who is sponsoring clinical trial NCT04169529?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.